

ROCHE - Erivedge (Vismodegib) approved for Locally Advanced or Metastatic BCC in US

<https://marketpublishers.com/r/R9B0F10AF51EN.html>

Date: January 2012

Pages: 5

Price: US\$ 90.00 (Single User License)

ID: R9B0F10AF51EN

Abstracts

Yesterday, ROG and Curis jointly announced that the USFDA approved once daily Erivedge, oral, first in class hedgehog inhibitor earlier than the action date for the treatment of locally advanced or metastatic basal cell carcinoma in adults. It is the first drug to be approved for this indication. Erivedge will be available in specialty pharmacies in US within one or two weeks. Roche has the marketing rights for Vismodegib excluding Japan and Korea where Chugai will market. Curis involved in the drug development and will receive royalties from sales.

Contents

COMPANIES MENTIONED

ROCHE

I would like to order

Product name: ROCHE - Erivedge (Vismodegib) approved for Locally Advanced or Metastatic BCC in US

Product link: <https://marketpublishers.com/r/R9B0F10AF51EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9B0F10AF51EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970